Financial Times  Nov 19  Comment 
Novo Banco created in August out of a €4.9bn bailout is the biggest item on the sales list
FiercePharma  Nov 18  Comment 
Big Pharma earned gold stars in 2014, as the industry's top drugmakers did more to get their meds to patients in the world's poorest countries. But despite recent progress, companies still have room to grow in R&D and distribution, the Index notes.
FierceBiotech  Nov 4  Comment 
In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as it works to build a portfolio of such treatments.
GenEng News  Oct 31  Comment 
Novo Nordisk is investing around DKK 750 million ($130 million) in new laboratories at the firm's R&D campus in Måløv, Denmark. Construction is already underway for the new facility, dubbed Diabetes Research House, which Novo Nordisk says will...
FiercePharma  Oct 30  Comment 
Novo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next year, the Danish drugmaker said it's expecting growth in the high single digits.
FierceBiotech  Oct 30  Comment 
Novo Nordisk is sounding a more cautious tone on Tresiba, its once-rejected new insulin. After hinting at an accelerated trip back to the FDA for the long-acting diabetes treatment, the Danish drugmaker now says it could be another few years...
Reuters  Oct 30  Comment 
Denmark's Novo Nordisk said on Thursday that it would provide an update on whether or not to list its IT subsidiary NNIT on January 30, when it provides its next earnings...
Wall Street Journal  Oct 30  Comment 
Denmark’s Novo Nordisk, the world’s largest maker of insulin, said that it expects high single-digit sales growth and around 10% operating profit growth in 2015, as it reported a rise in third-quarter net profit.
Wall Street Journal  Oct 30  Comment 

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki